l-carnitine tmao koeth 2013 nature medicine γ–Butyrobetaine is a pro-atherogenic intermediate in gut microbial metabolism of to L-Carnitine intake and high trimethylamine
L Carnitine intake and high trimethylamine N oxide plasma levels correlate with low aortic lesions in ApoE transgenic mice expressing CETP ScienceDirect Butyrobetaine Is a Proatherogenic Intermediate in Gut Microbial Metabolism of L Carnitine to TMAO: Cell Metabolism Frontiers TMAO as a potential biomarker and therapeutic target for chronic kidney disease: A review Frontiers Impacts of intestinal microbiota metabolite trimethylamine N oxide on cardiovascular disease: a bibliometric analysis The gutbrain axis and trimethylamine N oxide: an emergent biomarker in neurological diseases ScienceDirect
Pay in 4 interest-free payments of $6.02 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 15 - Sep 20




